The Jazz Pharmaceuticals PLC (JAZZ) share price is expected to increase by 47.13% over the next year. This is based on calculating the average 12-month share price estimate provided by 11 stock analysts who have covered JAZZ. Price targets range from $135.00 at the low end to $235.00 at the high end. The current analyst consensus for JAZZ is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
JAZZ is a stock in Health Care which has been forecasted to be worth $185.91 as an average. On the higher end, the forecast price is $235.00 USD by balaji prasad from Barclays and on the lower end JAZZ is forecasted to be $135.00 by ashwani verma from UBS.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
balaji prasad Barclays | Buy | $235.0 | maintained | Feb 7, 2024 |
david amsellem Piper Sandler | Buy | $171.0 | reiterated | Jan 3, 2024 |
gregory renza RBC Capital | Buy | $195.0 | maintained | Jan 3, 2024 |
jason gerberry Bank of America Securities | Buy | $184.0 | reiterated | Jan 2, 2024 |
joel beatty Robert W. Baird | Buy | $160.0 | initiatedcoverage | Jan 2, 2024 |
annabel samimy Stifel Nicolaus | Buy | $225.0 | rated | Dec 22, 2023 |
mohit bansal Wells Fargo | Hold | $140.0 | maintained | Dec 21, 2023 |
jessica fye J.P. Morgan | Buy | None | maintained | Dec 21, 2023 |
marc goodman Leerink Partners | Buy | $220.0 | maintained | Dec 17, 2023 |
ami fadia Needham | Buy | $225.0 | maintained | Nov 28, 2023 |
akash tewari Jefferies | Buy | $155.0 | maintained | Nov 28, 2023 |
ashwani verma UBS | Hold | $135.0 | downgraded | Nov 27, 2023 |
joon lee Truist Financial | Buy | $200.0 | maintained | Nov 9, 2023 |
joseph thome TD Cowen | Buy | $225.0 | maintained | Nov 8, 2023 |
gary nachman Raymond James | Hold | None | initiatedcoverage | Sep 28, 2023 |
charles duncan Cantor Fitzgerald | Buy | $180.0 | maintained | Aug 14, 2023 |
oren livnat H.C. Wainwright | Buy | $204.0 | reiterated | Aug 11, 2023 |
daniel busby RBC Capital | Buy | $201.0 | maintained | Aug 10, 2023 |
madhu kumar Goldman Sachs | Buy | $197.78 | maintained | Jun 22, 2023 |
jeffrey hung Morgan Stanley | Hold | $187.0 | rated | Mar 2, 2023 |
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
When did it IPO
2007
Staff Count
2,800
Country
Ireland
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Bruce C. Cozadd
Market Cap
$7.98B
In 2023, JAZZ generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that JAZZ's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywavu00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adults with Narcolepsy at World Sleep 2023
Mon, 23 Oct 2023
APLS-USD
$67.59
LNW-USD
$89.71
PCVX-USD
$75.26
APPF-USD
$230.24
GNTX-USD
$35.26
PARA-USD
$12